Anocca Raises SEK 440 Million to Advance T-Cell Therapy Development

Anocca AB, a clinical-stage T-cell immunotherapy company based in Sweden, has raised approximately SEK 440 million (USD 46 million) in new financing. The funds will support the ongoing development of VIDAR-1, Anocca’s gene-edited TCR-T cell therapy targeting mutant KRAS in pancreatic cancer, and advance its preclinical programs.

The financing round was led by Mellby Gård with participation from AMF, Ramsbury, existing shareholders, and new investors.

Recruitment is now open for the Phase I trial of VIDAR-1, which will take place at university hospitals in Sweden, Denmark, Germany, and the Netherlands.

Anocca’s CEO, Reagan Jarvis, thanked investors for their continued support and highlighted the company’s progress in bringing its first TCR-T cell therapy to patients. Mellby Gård Chairman Johan Andersson noted the company’s transition into a clinical-stage biotech as an important milestone.

SEB Corporate Finance served as financial advisor, with Mannheimer Swartling and HWF Advokater as legal advisors.

About Anocca
Anocca is a fully integrated biopharmaceutical company developing T-cell receptor-engineered T cell (TCR-T) therapies for solid tumours and other diseases. With proprietary technologies, in-house manufacturing, and more than 130 staff from over 40 countries, Anocca operates from Södertälje, Sweden.